Agenus Inc. (NASDAQ:AGEN) saw unusually-high trading volume on Monday . Approximately 1,140,017 shares were traded during mid-day trading, a decline of 5% from the previous session’s volume of 1,203,946 shares.The stock last traded at $6.51 and had previously closed at $6.22.

AGEN has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Agenus in a research report on Sunday, July 31st. Jefferies Group raised their price target on shares of Agenus from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Friday, July 29th. Maxim Group restated a “buy” rating and set a $7.00 price target on shares of Agenus in a report on Friday, June 10th. Finally, Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “hold” rating in a report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Agenus has an average rating of “Buy” and an average target price of $10.25.

The firm’s market capitalization is $562.32 million. The stock’s 50 day moving average price is $5.52 and its 200-day moving average price is $4.28.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, July 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $6.59 million for the quarter, compared to analyst estimates of $5.12 million. On average, equities analysts predict that Agenus Inc. will post ($1.27) EPS for the current fiscal year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.